Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Etiopathogenesis of autoimmune hepatitis.

Floreani A, Restrepo-Jiménez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, Bowlus CL, Gershwin ME, Anaya JM.

J Autoimmun. 2018 Dec;95:133-143. doi: 10.1016/j.jaut.2018.10.020. Epub 2018 Oct 29. Review.

PMID:
30385083
2.

Current Treatment Options for Primary Biliary Cholangitis.

Wong KA, Bahar R, Liu CH, Bowlus CL.

Clin Liver Dis. 2018 Aug;22(3):481-500. doi: 10.1016/j.cld.2018.03.003. Epub 2018 May 19. Review.

PMID:
30259848
3.

RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.

Hu Y, French SW, Chau T, Liu HX, Sheng L, Wei F, Stondell J, Garcia JC, Du Y, Bowlus CL, Wan YY.

FASEB J. 2018 Sep 25:fj201801390R. doi: 10.1096/fj.201801390R. [Epub ahead of print]

PMID:
30252536
4.

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.

Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL; GS-US-321-0102 Investigators.

Hepatology. 2018 Aug 28. doi: 10.1002/hep.30237. [Epub ahead of print]

PMID:
30153359
5.

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M.

Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145. [Epub ahead of print] No abstract available.

PMID:
30070375
6.

Primary sclerosing cholangitis: A review and update.

Tabibian JH, Bowlus CL.

Liver Res. 2017 Dec;1(4):221-230. doi: 10.1016/j.livres.2017.12.002.

7.

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Bahar R, Wong KA, Liu CH, Bowlus CL.

Gastroenterol Hepatol (N Y). 2018 Mar;14(3):154-163.

8.

A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.

Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW.

Hepatol Commun. 2018 Mar 23;2(5):484-491. doi: 10.1002/hep4.1173. eCollection 2018 May.

9.

Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.

Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL.

Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30409-9. doi: 10.1016/j.cgh.2018.04.047. [Epub ahead of print]

PMID:
29705262
10.

Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment.

Lu M, Zhou Y, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, Anderson H, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Bowlus CL, Lindor K, Zhang T, Trudeau S, Li J, Rupp LB, Gordon SC; Fibrotic Liver Disease Consortium Investigators.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1342-1350.e1. doi: 10.1016/j.cgh.2017.12.033. Epub 2017 Dec 23.

PMID:
29277621
11.

The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.

Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F.

Clin Rev Allergy Immunol. 2018 Apr;54(2):282-294. doi: 10.1007/s12016-017-8655-y. Review.

PMID:
29256057
12.

Scratching the surface of cholestatic itch treatments.

Bowlus CL.

Hepatology. 2018 May;67(5):2045-2048. doi: 10.1002/hep.29698. Epub 2018 Apr 1. No abstract available.

PMID:
29194716
13.

Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.

Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, Safer R, Lenderking WR, Skalicky A, Kleinman L, Myers RP, Subramanian GM, McHutchison JG, Levy C, Bowlus CL, Kowdley K, Muir AJ.

Hepatology. 2018 Jul;68(1):155-165. doi: 10.1002/hep.29664. Epub 2018 May 10.

PMID:
29152767
14.

Evaluation of indeterminate biliary strictures.

Bowlus CL, Olson KA, Gershwin ME.

Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):749. doi: 10.1038/nrgastro.2017.154. Epub 2017 Nov 2.

PMID:
29094722
15.

Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems.

Lu M, Li J, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, Raebel MA, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Bowlus CL, Lindor K, Rupp LB, Gordon SC; FOLD Investigators.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1333-1341.e6. doi: 10.1016/j.cgh.2017.10.018. Epub 2017 Oct 21.

PMID:
29066370
16.

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14.

PMID:
28818518
17.

Common Variable Immunodeficiency and Liver Involvement.

Song J, Lleo A, Yang GX, Zhang W, Bowlus CL, Gershwin ME, Leung PSC.

Clin Rev Allergy Immunol. 2018 Dec;55(3):340-351. doi: 10.1007/s12016-017-8638-z. Review.

PMID:
28785926
18.

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marzioni M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrumpf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK.

Gut. 2018 Aug;67(8):1517-1524. doi: 10.1136/gutjnl-2016-313598. Epub 2017 Aug 4.

19.

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

Henriksen EKK, Viken MK, Wittig M, Holm K, Folseraas T, Mucha S, Melum E, Hov JR, Lazaridis KN, Juran BD, Chazouillères O, Färkkilä M, Gotthardt DN, Invernizzi P, Carbone M, Hirschfield GM, Rushbrook SM, Goode E; UK-PSC Consortium, Ponsioen CY, Weersma RK, Eksteen B, Yimam KK, Gordon SC, Goldberg D, Yu L, Bowlus CL, Franke A, Lie BA, Karlsen TH.

HLA. 2017 Oct;90(4):228-233. doi: 10.1111/tan.13076. Epub 2017 Jul 11.

PMID:
28695657
20.

Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics.

Tanaka T, Zhang W, Sun Y, Shuai Z, Chida AS, Kenny TP, Yang GX, Sanz I, Ansari A, Bowlus CL, Ippolito GC, Coppel RL, Okazaki K, He XS, Leung PSC, Gershwin ME.

Hepatology. 2017 Sep;66(3):885-895. doi: 10.1002/hep.29245. Epub 2017 Jul 20.

21.

Human β-Defensin 2 in Primary Sclerosing Cholangitis.

Chang C, Lleo A, Kananurak A, Grizzi F, Tsuneyama K, Invernizzi P, Bevins CL, Bowlus CL.

Clin Transl Gastroenterol. 2017 Mar 16;8(3):e80. doi: 10.1038/ctg.2017.8.

22.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group.

Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

23.

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR.

Haemophilia. 2017 Mar;23(2):198-206. doi: 10.1111/hae.13178. Epub 2017 Jan 25.

PMID:
28124511
24.

The evolution of natural history of primary sclerosing cholangitis.

Takakura WR, Tabibian JH, Bowlus CL.

Curr Opin Gastroenterol. 2017 Mar;33(2):71-77. doi: 10.1097/MOG.0000000000000333. Review.

25.

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.

Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller TJ, Gotthardt DN, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma RK, Wijmenga C, Marschall HU, Milkiewicz P, Pares A, Kontula K, Chazouillères O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Floreani A, Gulamhusein AF, Eaton JE, Schreiber S, Coltescu C, Bowlus CL, Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, Sandford RN, Alexander G, Gaffney DJ, Chapman RW, Hirschfield GM, de Andrade M; UK-PSC Consortium; International IBD Genetics Consortium; International PSC Study Group, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Anderson CA.

Nat Genet. 2017 Feb;49(2):269-273. doi: 10.1038/ng.3745. Epub 2016 Dec 19.

26.

Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.

Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, Bastani R, Chak EW, Chen MS Jr.

World J Gastroenterol. 2016 Oct 14;22(38):8584-8595.

27.

Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.

Bowlus CL, Kenney JT, Rice G, Navarro R.

J Manag Care Spec Pharm. 2016 Oct;22(10-a-s Suppl):S3-S15. Review.

28.

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.

Bowlus CL.

Hepat Med. 2016 Sep 1;8:89-95. doi: 10.2147/HMER.S91709. eCollection 2016. Review.

29.

The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.

Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, Bowlus CL, Gershwin ME, Wang Q, Ma X.

Clin Rev Allergy Immunol. 2017 Jun;52(3):424-435. doi: 10.1007/s12016-016-8583-2.

PMID:
27515672
30.

Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).

Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, Qi R, Leung PS, Bowlus CL, Gershwin ME.

Autoimmun Rev. 2016 Aug;15(8):795-800. doi: 10.1016/j.autrev.2016.03.019. Epub 2016 Mar 24. Review.

PMID:
27019050
31.

Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, Alpini G, Alvaro D, Boberg KM, Locati M, Torzilli G, Rimassa L, Piscaglia F, He XS, Bowlus CL, Yang GX, Gershwin ME, Invernizzi P.

Clin Exp Immunol. 2016 Jul;185(1):61-71. doi: 10.1111/cei.12776. Epub 2016 May 17.

32.

Management of symptom complexes in primary biliary cholangitis.

Kuo A, Kuo A, Bowlus CL.

Curr Opin Gastroenterol. 2016 May;32(3):204-9. doi: 10.1097/MOG.0000000000000254. Review.

PMID:
26825590
33.

Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.

Sarkar S, Bowlus CL.

Clin Liver Dis. 2016 Feb;20(1):67-77. doi: 10.1016/j.cld.2015.08.005. Epub 2015 Oct 6. Review.

34.

Proposed therapies in primary biliary cholangitis.

Floreani A, Sun Y, Zou ZS, Li B, Cazzagon N, Bowlus CL, Gershwin ME.

Expert Rev Gastroenterol Hepatol. 2016;10(3):371-382. doi: 10.1586/17474124.2016.1121810. Epub 2016 Jan 6. Review.

35.

Evaluation of indeterminate biliary strictures.

Bowlus CL, Olson KA, Gershwin ME.

Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):28-37. doi: 10.1038/nrgastro.2015.182. Epub 2015 Nov 3. Review. Erratum in: Nat Rev Gastroenterol Hepatol. 2017 Nov 02;:.

PMID:
26526122
36.

The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis.

Tomiyama T, Yang GX, Zhao M, Zhang W, Tanaka H, Wang J, Leung PS, Okazaki K, He XS, Lu Q, Coppel RL, Bowlus CL, Gershwin ME.

Cell Mol Immunol. 2017 Mar;14(3):276-284. doi: 10.1038/cmi.2015.86. Epub 2015 Sep 21.

37.
38.

Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis.

Rong G, Wang H, Bowlus CL, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Chen Y, An L, Yang Y, Gershwin ME.

Clin Rev Allergy Immunol. 2015 Jun;48(2-3):132-41. doi: 10.1007/s12016-015-8483-x. Review.

PMID:
25762349
39.

Advances in pharmacotherapy for primary biliary cirrhosis.

Mousa HS, Lleo A, Invernizzi P, Bowlus CL, Gershwin ME.

Expert Opin Pharmacother. 2015 Apr;16(5):633-43. doi: 10.1517/14656566.2015.998650. Epub 2014 Dec 29. Review.

40.

New therapies for primary biliary cirrhosis.

Floreani A, Franceschet I, Perini L, Cazzagon N, Gershwin ME, Bowlus CL.

Clin Rev Allergy Immunol. 2015 Jun;48(2-3):263-72. doi: 10.1007/s12016-014-8456-5. Review.

PMID:
25331740
41.

Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis.

Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB, Rothschild KJ, Bowlus CL, Adamopoulos IE, Leung PS, Janssen HJ, Cheung AC, Coltescu C, Gershwin ME.

Liver Int. 2015 Feb;35(2):642-51. doi: 10.1111/liv.12690. Epub 2014 Oct 10.

42.

Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis.

Zhang J, Zhang W, Leung PS, Bowlus CL, Dhaliwal S, Coppel RL, Ansari AA, Yang GX, Wang J, Kenny TP, He XS, Mackay IR, Gershwin ME.

Hepatology. 2014 Nov;60(5):1708-16. doi: 10.1002/hep.27313. Epub 2014 Sep 29.

43.

Diagnosis and classification of primary sclerosing cholangitis.

Yimam KK, Bowlus CL.

Autoimmun Rev. 2014 Apr-May;13(4-5):445-50. doi: 10.1016/j.autrev.2014.01.040. Epub 2014 Jan 11. Review.

PMID:
24424180
44.

The diagnosis of primary biliary cirrhosis.

Bowlus CL, Gershwin ME.

Autoimmun Rev. 2014 Apr-May;13(4-5):441-4. doi: 10.1016/j.autrev.2014.01.041. Epub 2014 Jan 11. Review.

45.

IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy.

Yang CY, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP, Bowlus CL, Yang GX, Leung PS, Ansari AA, Wu L, Coppel RL, Gershwin ME.

Hepatology. 2014 May;59(5):1944-53. doi: 10.1002/hep.26979. Epub 2014 Apr 1.

46.

Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study.

Chen MS Jr, Fang DM, Stewart SL, Ly MY, Lee S, Dang JH, Nguyen TT, Maxwell AE, Bowlus CL, Bastani R, Nguyen TT.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):782-91. doi: 10.1158/1055-9965.EPI-12-1399. Epub 2013 Apr 23.

47.

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.

Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Juran BD, Milkiewicz P, Rust C, Schramm C, Müller T, Srivastava B, Dalekos G, Nöthen MM, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen CY, Croucher PJ, Sterneck M, Teufel A, Mason AL, Saarela J, Leppa V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich SS, Thompson WK, Schork AJ, Næss S, Thomsen I, Mayr G, König IR, Hveem K, Cleynen I, Gutierrez-Achury J, Ricaño-Ponce I, van Heel D, Björnsson E, Sandford RN, Durie PR, Melum E, Vatn MH, Silverberg MS, Duerr RH, Padyukov L, Brand S, Sans M, Annese V, Achkar JP, Boberg KM, Marschall HU, Chazouillères O, Bowlus CL, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M; UK-PSCSC Consortium, Rioux JD, Alexander G, Bergquist A, Cho J, Schreiber S, Manns MP, Färkkilä M, Dale AM, Chapman RW, Lazaridis KN; International PSC Study Group, Franke A, Anderson CA, Karlsen TH; International IBD Genetics Consortium.

Nat Genet. 2013 Jun;45(6):670-5. doi: 10.1038/ng.2616. Epub 2013 Apr 21.

48.

Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial.

Hsu L, Bowlus CL, Stewart SL, Nguyen TT, Dang J, Chan B, Chen MS Jr.

Dig Dis Sci. 2013 Mar;58(3):807-14. doi: 10.1007/s10620-012-2396-9. Epub 2012 Oct 17.

49.

Immunological orchestration of liver fibrosis.

Tanaka H, Leung PS, Kenny TP, Gershwin ME, Bowlus CL.

Clin Rev Allergy Immunol. 2012 Dec;43(3):220-9. doi: 10.1007/s12016-012-8323-1. Review.

PMID:
22695942
50.

The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis.

Kawata K, Kobayashi Y, Gershwin ME, Bowlus CL.

Clin Rev Allergy Immunol. 2012 Dec;43(3):230-41. doi: 10.1007/s12016-012-8324-0. Review.

PMID:
22689287

Supplemental Content

Loading ...
Support Center